Certara (CERT) Set to Post Quarterly Earnings on Thursday

Certara (NASDAQ:CERT) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Certara to announce earnings of $0.0866 per share and revenue of $91.98 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%. The company had revenue of $93.27 million for the quarter, compared to analyst estimates of $98.09 million. During the same quarter in the prior year, the company earned $0.07 earnings per share. The business’s revenue was down 10.8% compared to the same quarter last year. On average, analysts expect Certara to post $0.22 EPS for the current fiscal year and $0.28 EPS for the next fiscal year.

Certara Stock Performance

Certara stock opened at $11.48 on Thursday. The firm has a market capitalization of $1.75 billion, a P/E ratio of -25.51 and a beta of 1.42. The stock has a fifty day moving average price of $8.91 and a two-hundred day moving average price of $7.28. Certara has a 52-week low of $4.45 and a 52-week high of $12.29. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on CERT shares. Barclays upped their target price on shares of Certara from $7.50 to $9.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. KeyCorp boosted their price target on shares of Certara from $9.00 to $12.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. Weiss Ratings cut shares of Certara from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. UBS Group lowered shares of Certara from a “buy” rating to a “neutral” rating and set a $10.00 price objective for the company. in a report on Wednesday, September 30th. Finally, TD Cowen lifted their target price on shares of Certara from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Certara has an average rating of “Hold” and an average price target of $9.18.

Certara Company Profile

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.